14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IBO vs CLYM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas CLYM carries 41.9/100 (SELL) at $10.00 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While CLYM currently prints a higher short-term Unified Composite Score (41.9/100 SELL vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY).
Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both IBO (36.8/100 SELL) and CLYM (41.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs CLYM. Trailing 12-month operating profitability (IBO -12621.0% vs CLYM 0.0%) and valuation multiples (IBO N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $638.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IBO vs CLYM Key Questions & Quantitative Answers
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas CLYM carries 41.9/100 (SELL) at $10.00 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CLYM currently prints a higher short-term Unified Composite Score (41.9/100 SELL vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY). Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both IBO (36.8/100 SELL) and CLYM (41.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
IBO leads the Growth & Scale pillar: IBO posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (N/A gross margin, -12621.0% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IBO generates $2.3M in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, IBO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.
IBO screens cheaper on headline valuation multiples. IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 18.2x EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBO (71.2% ROE) versus CLYM (-29.3% ROE) capital efficiency.
In options market volatility and institutional positioning, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.75β · 120% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 114% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.